gvtcx

(NU/1257) Clinical Trial Unit or Contracted Research Organisation to set up and manage Vision DMD Phase 2b and extension study

NEWCASTLE UNIVERSITY Published 20 Feb 2017 Contracts Finder

key details

Value£800,000
Statusactive
Category (CPV) 73000000
RegionNorth East
Deadline22 Mar 2017
Contract start17 Apr 2017
Contract end30 Nov 2020
Procedureopen
SME suitableNo
OCIDocds-b5fd17-989673a5-c903-48f8-ae81-eaf4c1fa503c

description

This is an EU Open Tender. The scope of this contract relates specifically to the Phase 2b Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) and the extension study that will follow this. A registered Clinical Trial Unit (CTU) or Contracted Research Organisation (CRO) is required to set up and manage the clinical trial at sites in [UK/Australia/Israel/Sweden]. The CTU / CRO will be carrying out delegated duties on behalf of the sponsor, ReveraGen, but will be receiving payments for these duties from the Vision-DMD Horizon 2020 grant, coordinated by Newcastle University. This contract consists of 4 separate geographical Lots:

Lot 1:UK
Lot 2:Australia
Lot 3:Israel
Lot 4:Sweden

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
20 Feb 2017 Tender (tender) · 96e28e25-6c8c-44f9-92ee-e94c9209aa9e-131149

more from NEWCASTLE UNIVERSITY

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.